Sep 29, 2023 7:30am EDT Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy
Aug 7, 2023 4:30 pm EDT Capricor Therapeutic Second Quarter 2023 Financial Results and Corporate Update Conference Call